FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4316465976> ?p ?o ?g. }

• W4316465976 endingPage "178" @default.
• W4316465976 startingPage "178" @default.
• W4316465976 abstract "Background and objectives: EG-Mirotin (active ingredient EGT022) targets nonproliferative diabetic retinopathy (NPDR), the early stage of retinopathy. EG-Mirotin reverses capillary damage before NPDR progresses to an irreversible stage. EG-Mirotin safety and efficacy were investigated in patients with type 1 or type 2 diabetes mellitus and moderate to severe NPDR. Methods: In this open-label, single-arm, single-center, exploratory phase II study, 10 patients (20 eyes) received EG-Mirotin once a day (3 mg/1.5 mL sterile saline) for 5 days and were evaluated for ischemic index changes and safety. End of study was approximately 8 ± 1 weeks (57 ± 7 days) after the first drug administration. Results: EG-Mirotin injections were well tolerated, with no dose-limiting adverse events, serious adverse events, or deaths. Four treatment-emergent adverse events (TEAEs) unrelated to the investigational drug were observed in 2 out of 10 participants (20%) who had received the investigational drug. The overall average percent change in ischemic index at each evaluation point compared with baseline was statistically significant (Greenhouse–Geisser F = 9.456, p = 0.004 for the main effect of time), and a larger change was observed when the baseline ischemic index value was high (Greenhouse–Geisser F = 10.946, p = 0.002 for time × group interaction). Conclusions: The EG-Mirotin regimen established in this study was shown to be feasible and safe and was associated with a trend toward potential improvement in diabetes-induced ischemia and retinal capillary leakage." @default.
• W4316465976 created "2023-01-16" @default.
• W4316465976 creator A5007572599 @default.
• W4316465976 creator A5025653247 @default.
• W4316465976 creator A5040302662 @default.
• W4316465976 creator A5059051692 @default.
• W4316465976 creator A5078372604 @default.
• W4316465976 date "2023-01-16" @default.
• W4316465976 modified "2023-10-14" @default.
• W4316465976 title "A Nonrandomized Phase 2 Trial of EG-Mirotin, a Novel, First-in-Class, Subcutaneously Deliverable Peptide Drug for Nonproliferative Diabetic Retinopathy" @default.
• W4316465976 cites W1870327063 @default.
• W4316465976 cites W1897305042 @default.
• W4316465976 cites W1915008606 @default.
• W4316465976 cites W1918578211 @default.
• W4316465976 cites W1966206262 @default.
• W4316465976 cites W1999143095 @default.
• W4316465976 cites W2008517546 @default.
• W4316465976 cites W2012955036 @default.
• W4316465976 cites W2020865074 @default.
• W4316465976 cites W2027475042 @default.
• W4316465976 cites W2027957604 @default.
• W4316465976 cites W2059843925 @default.
• W4316465976 cites W2078916806 @default.
• W4316465976 cites W2082363445 @default.
• W4316465976 cites W2084678823 @default.
• W4316465976 cites W2094935740 @default.
• W4316465976 cites W2095426581 @default.
• W4316465976 cites W2138337378 @default.
• W4316465976 cites W2139333998 @default.
• W4316465976 cites W2167963794 @default.
• W4316465976 cites W2171651020 @default.
• W4316465976 cites W2340514915 @default.
• W4316465976 cites W2423787249 @default.
• W4316465976 cites W2438759427 @default.
• W4316465976 cites W2741058611 @default.
• W4316465976 cites W2886924097 @default.
• W4316465976 cites W2900068552 @default.
• W4316465976 cites W2938669378 @default.
• W4316465976 cites W2972869264 @default.
• W4316465976 cites W2987780301 @default.
• W4316465976 cites W3024607760 @default.
• W4316465976 cites W3024956298 @default.
• W4316465976 cites W3096531252 @default.
• W4316465976 cites W3111078905 @default.
• W4316465976 cites W4200451243 @default.
• W4316465976 cites W4200610801 @default.
• W4316465976 cites W4212790134 @default.
• W4316465976 cites W4311522248 @default.
• W4316465976 cites W4324113931 @default.
• W4316465976 cites W585163460 @default.
• W4316465976 cites W74808756 @default.
• W4316465976 doi "https://doi.org/10.3390/medicina59010178" @default.
• W4316465976 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36676801" @default.
• W4316465976 hasPublicationYear "2023" @default.
• W4316465976 type Work @default.
• W4316465976 citedByCount "1" @default.
• W4316465976 countsByYear W43164659762023 @default.
• W4316465976 crossrefType "journal-article" @default.
• W4316465976 hasAuthorship W4316465976A5007572599 @default.
• W4316465976 hasAuthorship W4316465976A5025653247 @default.
• W4316465976 hasAuthorship W4316465976A5040302662 @default.
• W4316465976 hasAuthorship W4316465976A5059051692 @default.
• W4316465976 hasAuthorship W4316465976A5078372604 @default.
• W4316465976 hasBestOaLocation W43164659761 @default.
• W4316465976 hasConcept C126322002 @default.
• W4316465976 hasConcept C134018914 @default.
• W4316465976 hasConcept C141071460 @default.
• W4316465976 hasConcept C197934379 @default.
• W4316465976 hasConcept C203092338 @default.
• W4316465976 hasConcept C2777180221 @default.
• W4316465976 hasConcept C2779829184 @default.
• W4316465976 hasConcept C2781413609 @default.
• W4316465976 hasConcept C535046627 @default.
• W4316465976 hasConcept C555293320 @default.
• W4316465976 hasConcept C71924100 @default.
• W4316465976 hasConceptScore W4316465976C126322002 @default.
• W4316465976 hasConceptScore W4316465976C134018914 @default.
• W4316465976 hasConceptScore W4316465976C141071460 @default.
• W4316465976 hasConceptScore W4316465976C197934379 @default.
• W4316465976 hasConceptScore W4316465976C203092338 @default.
• W4316465976 hasConceptScore W4316465976C2777180221 @default.
• W4316465976 hasConceptScore W4316465976C2779829184 @default.
• W4316465976 hasConceptScore W4316465976C2781413609 @default.
• W4316465976 hasConceptScore W4316465976C535046627 @default.
• W4316465976 hasConceptScore W4316465976C555293320 @default.
• W4316465976 hasConceptScore W4316465976C71924100 @default.
• W4316465976 hasIssue "1" @default.
• W4316465976 hasLocation W43164659761 @default.
• W4316465976 hasLocation W43164659762 @default.
• W4316465976 hasLocation W43164659763 @default.
• W4316465976 hasOpenAccess W4316465976 @default.
• W4316465976 hasPrimaryLocation W43164659761 @default.
• W4316465976 hasRelatedWork W1563850031 @default.
• W4316465976 hasRelatedWork W2003938723 @default.
• W4316465976 hasRelatedWork W2047967234 @default.
• W4316465976 hasRelatedWork W2118496982 @default.
• W4316465976 hasRelatedWork W2364998975 @default.
• W4316465976 hasRelatedWork W2369162477 @default.

• next